EUVIMEDEUVIMED entdecken
Crossref

Do current oral ciprofloxacin regimens achieve pharmacokinetic/pharmacodynamic targets within safe exposure limits in older adults with Pseudomonas aeruginosa infection? A population pharmacokinetic analysis

Mehdi El Hassani, Daniel J G Thirion iD, Aysenur Yaliniz, Katherine Desforges, Josée Verdon, Emily G McDonald iD, Amélie Marsot

Journal of Antimicrobial Chemotherapy · 04.08.2026 · 81 (9)

DOI: 10.1093/jac/dkag283 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 14.08.2026. Verfasst von Mehdi El Hassani und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Université de Montréal, Montréal, Canada. Hauptthemen laut MEDLINE: Ciprofloxacin, Pseudomonas Infections, Anti-Bacterial Agents, Pseudomonas aeruginosa. Die Arbeit nennt 45 Literaturangaben. Gefördert von: Fonds de Recherche du Québec-Santé, Réseau Québécois de Recherche sur les Médicaments, Canada Foundation for Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ciprofloxacin is one of the few orally available antibiotics with activity against Pseudomonas aeruginosa. This study developed a population pharmacokinetic (popPK) model for oral ciprofloxacin in older adults and evaluated whether standard regimens achieve the pharmacokinetic/pharmacodynamic (PK/PD) target of 24 h area under the concentration–time curve over minimal inhibitory concentration (AUC0-24/MIC) ≥ 125.

Methods

This was a prospective pilot study in patients ≥75 years taking oral ciprofloxacin at the McGill University Health Centre, Canada. Plasma samples were collected at steady state (peak, mid-interval, trough) and data fitting was performed using NONMEM with stochastic approximation expectation–maximization. Monte Carlo simulations (n = 1000) assessed the probability of target attainment (PTA) for standard dosing regimens of 250–750 mg q12h across MICs of 0.125–2 mg/L.

Results

Fifteen patients (median age 82 years, weight 75 kg, creatinine clearance 46 mL/min) contributed 42 plasma concentrations to the analysis. A one-compartment model with first-order absorption and elimination best described the data. Population mean apparent clearance and volume of distribution were 14.3 L/h and 247 L, respectively (resulting in a 12 h half-life), with high interindividual variability (IIV: 75.2% and 36.0%). The absorption rate constant was fixed to 2.5 h−1. No covariate effects were retained in the final model. At the P. aeruginosa clinical MIC breakpoint of 0.5 mg/L, standard regimens achieved PTAs of 18.7% (250 mg q12h), 56.6% (500 mg q12h), and 76.5% (750 mg q12h).

Conclusions

This first popPK model for oral ciprofloxacin specifically in older adults demonstrates that simulated standard dosing regimens fail to achieve PK/PD targets for P. aeruginosa. The large IIV, increased drug exposure and low target attainment support implementation of therapeutic drug monitoring in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CiprofloxacinPseudomonas InfectionsAnti-Bacterial AgentsPseudomonas aeruginosaHumansAged, 80 and overAgedFemaleAdministration, OralMicrobial Sensitivity TestsProspective StudiesMalePilot ProjectsMonte Carlo MethodPlasmaCanada

Substanzen

CiprofloxacinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Faculty of Pharmacy, Université de Montréal, Montréal, Canada.
  • Department of Pharmacy, McGill University Health Centre, Montréal, Canada.
  • Department of Medicine, McGill University Health Centre, Montréal, Canada.

ORCID-Profile: Daniel J G Thirion, Emily G McDonald

Förderung

  • Fonds de Recherche du Québec-Santé
  • Réseau Québécois de Recherche sur les Médicaments
  • Canada Foundation for Innovation
  • CSHP Research and Education Foundation

Zitieren

APA

El Hassani, M., Thirion, D. J. G., Yaliniz, A., Desforges, K., Verdon, J., McDonald, E. G., & Marsot, A. (2026). Do current oral ciprofloxacin regimens achieve pharmacokinetic/pharmacodynamic targets within safe exposure limits in older adults with Pseudomonas aeruginosa infection? A population pharmacokinetic analysis. Journal of Antimicrobial Chemotherapy, 81(9). https://doi.org/10.1093/jac/dkag283

Vancouver

El Hassani M, Thirion DJG, Yaliniz A, Desforges K, Verdon J, McDonald EG, et al. Do current oral ciprofloxacin regimens achieve pharmacokinetic/pharmacodynamic targets within safe exposure limits in older adults with Pseudomonas aeruginosa infection? A population pharmacokinetic analysis. Journal of Antimicrobial Chemotherapy. 2026;81(9). doi:10.1093/jac/dkag283

BibTeX
@article{ElHassani2026,
  author = {El Hassani, Mehdi and Thirion, Daniel J G and Yaliniz, Aysenur and Desforges, Katherine and Verdon, Josée and McDonald, Emily G and Marsot, Amélie},
  title = {Do current oral ciprofloxacin regimens achieve pharmacokinetic/pharmacodynamic targets within safe exposure limits in older adults with Pseudomonas aeruginosa infection? A population pharmacokinetic analysis},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  volume = {81},
  number = {9},
  doi = {10.1093/jac/dkag283}
}
Kostenlos starten →